KR880002537A - Herbal Medicine - Google Patents

Herbal Medicine Download PDF

Info

Publication number
KR880002537A
KR880002537A KR1019870008981A KR870008981A KR880002537A KR 880002537 A KR880002537 A KR 880002537A KR 1019870008981 A KR1019870008981 A KR 1019870008981A KR 870008981 A KR870008981 A KR 870008981A KR 880002537 A KR880002537 A KR 880002537A
Authority
KR
South Korea
Prior art keywords
composition
octreotide
composition according
powder
nasal
Prior art date
Application number
KR1019870008981A
Other languages
Korean (ko)
Inventor
모이제 아즈리아 독토르
토마스 카반악 독토르
볼프강 도에프니 독토르
안드레아스 룸멜트 독토르
Original Assignee
원본미기재
산도즈 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB868620035A external-priority patent/GB8620035D0/en
Priority claimed from GB868626821A external-priority patent/GB8626821D0/en
Application filed by 원본미기재, 산도즈 리미티드 filed Critical 원본미기재
Publication of KR880002537A publication Critical patent/KR880002537A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins

Abstract

내용 없음No content

Description

생약제제Herbal Medicine

본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음Since this is an open matter, no full text was included.

Claims (26)

옥트레오티드를 포함하는 비강약학 조성물.Nasal pharmaceutical compositions comprising octreotide. 제1항에 있어서, 단위투약량당 0.1 내지 3mg의 옥트레오티드를 함유하도록된 것을 특징으로 하는 조성물.2. A composition according to claim 1 which is adapted to contain 0.1 to 3 mg of octreotide per unit dose. 제1항에 있어서, 단위투약략당 0.1내지 1mg의 옥트레오티드를 함유하도록된 것을 특징으로 하는 조성물.The composition of claim 1, wherein the composition is adapted to contain 0.1 to 1 mg of octreotide per unit dose. 제1항에 있어서, 단위투약략당 0.6내지 1mg을 함유하도록 된것을 특징으로 하는 조성물.The composition of claim 1, wherein the composition contains 0.6 to 1 mg per unit dosage. 제1항 내지 제4항중 어느 한 항에 있어서, 액체 형태인 것을 특징으로 하는 조성물.The composition according to any one of claims 1 to 4, which is in liquid form. 제5항에 있어서, 수용액 형태인 것을 특징으로 하는 조성물.The composition of claim 5 in the form of an aqueous solution. 제1항 내지 제4항중 어느 한 항에 있어서, 비강삽입재 형태인 것을 특징으로 하는 조성물.The composition according to any one of claims 1 to 4, which is in the form of a nasal insert. 제1항 내지 제4항중 어느 한 항에 있어서, 분말 형태인 것을 특징으로 하는 조성물.The composition according to claim 1, which is in powder form. 제8항에 있어서, 옥트레오티드층으로 피복된 입자를 함유하는 것을 특징으로 하는 조성물.9. A composition according to claim 8, containing particles coated with an octreotide layer. 제8항 또는 제9항에 있어서, 상기 분말이 히드록시프로필 메틸 셀룰로스를 함유하는 입자로 구성되는 것을 특징으로 하는 조성물.10. The composition according to claim 8 or 9, wherein the powder consists of particles containing hydroxypropyl methyl cellulose. 제8항 또는 제9항에 있어서 상기 분말이 락토스를 함유하는 입자로 구성되는 것을 특징으로 하는 조성물.10. The composition of claim 8 or 9, wherein said powder consists of particles containing lactose. 제8항 또는 제9항에 있어서, 상기 분말이 미세결정성 셀룰로스를 함유하는 입자로 구성되는 것을 특징으로 하는 조성물.10. The composition of claim 8 or 9, wherein the powder consists of particles containing microcrystalline cellulose. 제8항 내지 제13중 어느 한 항에 있어서, 분말 20mg당 0.2 내지 1,6mg의 옥트레오티드를 함유하는 것을 특징으로 하는 조성물.The composition according to any one of claims 8 to 13, which contains 0.2 to 1,6 mg of octreotide per 20 mg of powder. 제8항에 있어서, 분말 20mg당 0.2mg의 옥트레오티드를 함유하는 것을 특징으로 하는 조성물.The composition of claim 8 containing 0.2 mg of octreotide per 20 mg of powder. 제8항에 있어서, 분말 20mg당 0.4mg의 옥트레오티드를 함유하는 것을 특징으로 하는 조성물.The composition of claim 8 which contains 0.4 mg of octreotide per 20 mg of powder. 제8항에 있어서, 분말 20mg당 0.8mg의 옥트레오티드를 함유하는 것을 특징으로 하는 조성물.The composition of claim 8 which contains 0.8 mg of octreotide per 20 mg of powder. 제8항에 있어서, 분말 20mg당 1.6mg의 옥트레오티드를 함유하는 것을 특징으로 하는 조성물.9. A composition according to claim 8 which contains 1.6 mg of octreotide per 20 mg of powder. 제8항 내지 제17항중 어느 한 항에 있어서, 입자에 대한 옥트레오티드의 중량비가 10내지 100인것을 특징으로 하는 조성물.18. The composition according to any one of claims 8 to 17, wherein the weight ratio of octreotide to particles is between 10 and 100. 제1항 내지 제18항중 어느 한 항에 있어서, 단위 투약형태인 것을 특징으로 하는 조성물.19. A composition according to any one of the preceding claims in the unit dosage form. 제19항에 있어서, 캡슐인 것을 특징으로 하는 조성물.20. The composition of claim 19, which is a capsule. 제1항 내지 제20항중 어느 한 항에 있어서, 비강도포구인 것을 특징으로 하는 조성물.The composition according to any one of claims 1 to 20, which is a nasal cavity. 제21항에 있어서, 에어로졸장치인 것을 특징으로 하는 조성물.A composition according to claim 21, which is an aerosol device. 제22항에 있어서, 상기 에어로졸장치가 액상촉진제를 함유하는 것을 특징으로 하는 조성물.23. The composition of claim 22, wherein said aerosol device contains a liquid accelerator. 실시예중의 하나에 의거하여 전술한 바와 같은 비강옥트레오티드 조성물.A nasal octored composition as described above in accordance with one of the examples. 치료적 유효량을 비점막에 투여하는 것을 특징으로 하는 옥트레오티드 투여방법.An octreotide administration method comprising administering a therapeutically effective amount to the nasal mucosa. 비강양학 조성물 제조시의 옥트레오티드의 사용방법.Use of octreotide in the preparation of nasal dose compositions. ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.※ Note: The disclosure is based on the initial application.
KR1019870008981A 1986-08-18 1987-08-17 Herbal Medicine KR880002537A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB868620035A GB8620035D0 (en) 1986-08-18 1986-08-18 Organic compounds
GB8620035 1986-08-18
GB868626821A GB8626821D0 (en) 1986-11-10 1986-11-10 Organic compounds
GB8626821 1986-11-10

Publications (1)

Publication Number Publication Date
KR880002537A true KR880002537A (en) 1988-05-09

Family

ID=26291187

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019870008981A KR880002537A (en) 1986-08-18 1987-08-17 Herbal Medicine

Country Status (24)

Country Link
KR (1) KR880002537A (en)
AT (1) AT396331B (en)
AU (2) AU612589B2 (en)
BE (1) BE1001748A4 (en)
CA (1) CA1322331C (en)
CH (1) CH672252A5 (en)
CS (1) CS411491A3 (en)
DE (1) DE3726517A1 (en)
DK (1) DK428287A (en)
ES (1) ES2004807A6 (en)
FI (1) FI93307C (en)
FR (1) FR2602680B1 (en)
GR (1) GR871289B (en)
HK (1) HK80493A (en)
HU (1) HU200940B (en)
IE (1) IE60761B1 (en)
IL (1) IL83572A (en)
IT (1) IT1222510B (en)
LU (1) LU86971A1 (en)
NL (1) NL8701874A (en)
NO (1) NO175519C (en)
NZ (1) NZ221473A (en)
PT (1) PT85545B (en)
SE (1) SE8703183L (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110034381A1 (en) 2002-01-22 2011-02-10 David Kleinberg Methods for Therapeutic Treatment of Benign Prostatic Hypertrophy (BPH)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6034925B2 (en) * 1979-07-31 1985-08-12 帝人株式会社 Long-acting nasal preparation and its manufacturing method
CY1327A (en) * 1979-11-27 1986-06-27 Sandoz Ag Novel polypeptides,processes for their production,pharmaceutical compositions comprising said polypeptides and their use
US4451394A (en) * 1982-10-25 1984-05-29 American Home Products Corporation Dodecapeptides preventing glucose and triglyceride assimilation
JPS59163313A (en) * 1983-03-09 1984-09-14 Teijin Ltd Peptide hormone composition for nasal administration
US4505897A (en) * 1983-04-18 1985-03-19 The Administrators Of The Tulane Educational Fund Cyclic pentapeptides displaying somatostatin antagonism and method of treatment of mammals therewith
GB8514090D0 (en) * 1985-06-04 1985-07-10 Sandoz Ltd Organic compounds
US4612302A (en) * 1983-11-14 1986-09-16 Brigham And Women's Hospital Clinical use of somatostatin analogues
JPS60224616A (en) * 1984-04-24 1985-11-09 Teijin Ltd Composition for administration through nose
US4725577A (en) * 1985-04-25 1988-02-16 Administrators Of The Tulane Educational Fund Biologically active lysine containing octapeptides
JPH085913B2 (en) * 1985-09-12 1996-01-24 ザ・アドミニストレ−タ−ズ・オブ・ザ・ツ−レイン・エデユケイシヨナル・フアンド Therapeutic somatostatin congeners

Also Published As

Publication number Publication date
HUT46235A (en) 1988-10-28
FI93307C (en) 1995-03-27
IT1222510B (en) 1990-09-05
GR871289B (en) 1987-12-18
NO175519B (en) 1994-07-18
AU612589B2 (en) 1991-07-18
AU7712087A (en) 1988-02-25
NO873452L (en) 1988-02-19
ATA206087A (en) 1992-12-15
DE3726517A1 (en) 1988-03-03
AU8568991A (en) 1991-12-05
HK80493A (en) 1993-08-13
NO175519C (en) 1994-10-26
DK428287D0 (en) 1987-08-17
BE1001748A4 (en) 1990-02-27
ES2004807A6 (en) 1989-02-01
CS411491A3 (en) 1992-06-17
IT8721670A0 (en) 1987-08-18
IE60761B1 (en) 1994-08-10
CH672252A5 (en) 1989-11-15
CA1322331C (en) 1993-09-21
FR2602680B1 (en) 1993-04-16
HU200940B (en) 1990-09-28
IE872187L (en) 1988-02-18
IL83572A (en) 1992-09-06
SE8703183L (en) 1988-02-19
AT396331B (en) 1993-08-25
FI873548A0 (en) 1987-08-17
PT85545B (en) 1990-05-31
FI93307B (en) 1994-12-15
PT85545A (en) 1987-09-01
NL8701874A (en) 1988-03-16
NO873452D0 (en) 1987-08-17
LU86971A1 (en) 1988-03-02
FR2602680A1 (en) 1988-02-19
AU637530B2 (en) 1993-05-27
NZ221473A (en) 1990-08-28
FI873548A (en) 1988-02-19
DK428287A (en) 1988-02-19
SE8703183D0 (en) 1987-08-17
IL83572A0 (en) 1988-01-31

Similar Documents

Publication Publication Date Title
KR900701274A (en) Dosage formulations reduce the likelihood of abuse
ATE77947T1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING PENTAMIDINE.
KR920702216A (en) Use of Acetyl D-Carnitine in Glaucoma Treatment
GR3001238T3 (en) Process for the preparation of an administration and dosage for drugs, reagents or other active substances
ES2171469T3 (en) COMPOSITION ADMINISTERED BY NASAL AND PREPARATION THAT CONTAINS IT.
KR840000228A (en) Method for preparing dry powder in preparation mixture
BG100933A (en) Polymer coated tablets comprising amoxycilin and clavulanate
CA2149362A1 (en) Pharmaceutical composition based on guar gum coated with simethicone, inassociation with a neutralizing antacid
KR880002515A (en) Fast absorbing and acting sullindac or a mixture of sodium sullindak and base
NO20030897L (en) Process for the preparation of pharmaceutical compositions for use with wet gelatin formulations
KR850700109A (en) Antidiuretic DDAVP and its preparation method
NO890186D0 (en) PROCEDURE FOR THE PREPARATION OF A DELIVERY AND / OR DOSAGE FOR MEDICINAL ACTIVE SUBSTANCES.
KR830005854A (en) Method for preparing alkaline analgesic capsule
IE891919L (en) Pharmaceutical dosage form for the medication of fish
GB2181646A (en) Medicated chewing gum
KR830002510A (en) Composition consisting of biologically active compound and hydroxyalkyl starch
KR880007060A (en) Pharmaceutical composition
FI962056A (en) New pharmaceutical composition for the manufacture of stable powder containing as active ingredient a combination of acetylsalicylic acid and methoclopramide
MY102411A (en) Nasal solutions
KR930001926A (en) Pharmaceutical composition for the treatment of mental and neurological disorders
KR880002537A (en) Herbal Medicine
KR870009716A (en) Chlorfeniramine Formulation
MY101916A (en) Etoposide oral dosage form.
KR890007728A (en) Painkiller
KR830008678A (en) Analgesic composition

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application